From January 6 to 7, the National Drug Administration Work Conference was held in Beijing. The conference emphasized that 2026 should focus on achieving a good start to the “15th Five-Year Plan”, grasp the key points, outline the outline, and complete the following key tasks. The first is to make every effort to ensure a high level of drug safety. Improve the drug safety responsibility system, raise the level of clinical trial supervision, strengthen production supervision of high-risk varieties, increase inspection and sampling efforts on key varieties such as those selected for collection, carry out “clean-up” actions to consolidate and upgrade the drug business process, strengthen online sales supervision, and effectively adhere to the bottom line of drug safety. Second, actively support the development of the pharmaceutical industry to improve quality and efficiency. Comprehensively deepen drug supervision reform, implement the requirements of “early intervention, one enterprise, one policy, full guidance, research and review linkage” for key varieties, support pharmaceutical research and innovation, promote integrity, innovation and development of traditional Chinese medicine, support a high level of self-reliance and self-improvement in medical devices, and promote beautiful economic development and growth. The third is to continuously raise the level of legalization of drug supervision. Continue to improve the drug supervision laws and regulations system, improve the drug standards system, enhance the authority and credibility of administrative law enforcement, increase efforts to popularize the law to enterprises and the grassroots level, and further consolidate the legal foundation of drug supervision. Fourth, steadily push forward the modernization of drug supervision. Prepare the “15th Five-Year Plan” drug plan with high quality, solidly promote the integration of national drug supervision, strengthen the regulatory talent team and technical support capacity building, deepen the construction of regulatory informatization and scientific research application in drug supervision, participate deeply in global drug safety management, and push the international influence of China's drug regulation to a new level.

From January 6 to 7, the National Drug Administration Work Conference was held in Beijing. The conference emphasized that 2026 should focus on achieving a good start to the “15th Five-Year Plan”, grasp the key points, outline the outline, and complete the following key tasks. The first is to make every effort to ensure a high level of drug safety. Improve the drug safety responsibility system, raise the level of clinical trial supervision, strengthen production supervision of high-risk varieties, increase inspection and sampling efforts on key varieties such as those selected for collection, carry out “clean-up” actions to consolidate and upgrade the drug business process, strengthen online sales supervision, and effectively adhere to the bottom line of drug safety. Second, actively support the development of the pharmaceutical industry to improve quality and efficiency. Comprehensively deepen drug supervision reform, implement the requirements of “early intervention, one enterprise, one policy, full guidance, research and review linkage” for key varieties, support pharmaceutical research and innovation, promote integrity, innovation and development of traditional Chinese medicine, support a high level of self-reliance and self-improvement in medical devices, and promote beautiful economic development and growth. The third is to continuously raise the level of legalization of drug supervision. Continue to improve the drug supervision laws and regulations system, improve the drug standards system, enhance the authority and credibility of administrative law enforcement, increase efforts to popularize the law to enterprises and the grassroots level, and further consolidate the legal foundation of drug supervision. Fourth, steadily push forward the modernization of drug supervision. Prepare the “15th Five-Year Plan” drug plan with high quality, solidly promote the integration of national drug supervision, strengthen the regulatory talent team and technical support capacity building, deepen the construction of regulatory informatization and scientific research application in drug supervision, participate deeply in global drug safety management, and push the international influence of China's drug regulation to a new level.